Loading...
Loading...
COCP| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 103.0K |
| Gross Profit | -103.0K |
| Operating Expense | 5,111.0K |
| Operating I/L | -5,111.0K |
| Other Income/Expense | -78.0K |
| Interest Income | 0.0K |
| Pretax | -5,189.0K |
| Income Tax Expense | 78.0K |
| Net Income/Loss | -5,267.0K |
Cocrystal Pharma, Inc. is a biotechnology company specializing in the discovery and development of antiviral therapeutic treatments for serious and chronic viral diseases. The company utilizes structure-based technologies to create antiviral drugs, focusing on hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. Its product portfolio includes CC-31244, a HCV non-nucleoside polymerase inhibitor, and CC-42344, a PB2 inhibitor for influenza, both in various stages of clinical development. Cocrystal Pharma also collaborates with industry partners to develop proprietary antiviral agents and has ongoing research initiatives for the treatment of norovirus and coronavirus infections.
